Вештачка интелигенција

Amgen and PostEra Collaborate in Drug Discovery using Artificial Intelligence

Summary

In a groundbreaking partnership, biotechnology company PostEra has joined forces with Amgen to revolutionize drug discovery. The collaboration will leverage PostEra’s advanced artificial intelligence platform, Proton, along with Amgen’s expertise in drug discovery, to develop up to five small molecule […]

Amgen and PostEra Collaborate in Drug Discovery using Artificial Intelligence

In a groundbreaking partnership, biotechnology company PostEra has joined forces with Amgen to revolutionize drug discovery. The collaboration will leverage PostEra’s advanced artificial intelligence platform, Proton, along with Amgen’s expertise in drug discovery, to develop up to five small molecule programs.

The Proton platform is an innovative machine learning platform that facilitates the entire process of drug design, synthesis, and testing. By providing an efficient way to optimize this process, Proton helps accelerate the discovery of new drugs.

PostEra’s CEO, Aaron Morris, stated, “We believe that artificial intelligence can significantly enhance drug discovery, but we are also aware of the hype surrounding this technology. That is why we have worked hard to demonstrate the value of Proton in real research programs with multiple partners in different therapeutic areas.”

PostEra already collaborates with Pfizer since 2020, and their partnership was further expanded in 2022 with an upfront payment of $13 million and an additional $248 million in future stages. In January 2022, the company also raised $24 million in a Series A investment round.

Amgen previously announced a collaboration with Generate Medicines to utilize their machine learning-based technology for the discovery and development of protein therapies for patients.

FAQ: